New mesh device aims to relieve chest pain when other treatments fail

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Angina - Canadian Cardiovascular Society Class II-IV on at least two anti-anginals or maximally tolerated medical therapy if less than two.Hemodynamically significant epicardial coronary artery disease in the LAD, defined as an FFR≤0.80 and/or NHPR≤0.89. * No conventional revascularization options or considered unsuitable as determined by the local heart team. * Anatomically suitable for instrumentation of the left anterior descending coronary artery with a coronary pressure wire and infusion microcatheter. * Patient understands the nature of the procedure and provides written informed consent for the study prior to enrolment. Exclusion Criteria: * Age \< 18 years. * Absence of symptoms reported on the ORBITA-app during the 2-week screening period. * Mean right atrial pressure ≥15 mmHg * Severe pulmonary hypertension. * Coronary sinus anatomy not suitable for CSR implantation. * Pregnancy or planned pregnancy within the next 12 months. * Recent acute coronary syndrome (within 3 months). * Recent revascularization with PCI (within 6 months). * Severe arrhythmias, including chronic atrial fibrillation with persistent rapid ventricular response (\>100bpm despite medication). * Indication for cardiac resynchronization therapy. * Severe left ventricular impairment (left ventricular ejection fraction \<30%). * NYHA class IV or decompensated heart failure or hospitalization due to heart failure within 90 days before the index procedure. * Recent implantation of a permanent pacemaker or defibrillator lead in the right ventricle or atrium (within 90 days before the index procedure). * Presence of a pacemaker lead in the coronary sinus. * Severe valvular heart disease. * History of tricuspid valve replacement or repair. * Kidney failure (estimated glomerular filtration rate \<30ml/min) * Contra-indication to short term dual antiplatelet therapy or lifelong aspirin treatment. * Currently enrolled in another investigational device or drug trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints. * Unable or unwilling to use the ORBITA app * Known inability to tolerate contrast medium. * Life expectancy \<1 year.